We recently developed an enzyme-linked immunosorbent assay (ELISA) for total protein S (PSI antigen using the monoclonal antibody S-12. During the screening of thrombophilic patients we identified a patient, who was using marcoumar, with 0% PS by monoclonal ELSA and 23% PS by polyclonal ELISA. Further analysis of this patient and his family showed that the patient was a compound heterozygote for type I PS deficiency and for an abnormal PS molecule (PS-Heerlen) that was not recognized by the S-12 antibody. Similar observations were made in t w o sisters from an unrelated Dutch family. Subsequent studies showed that PS Heerlen has a slightly lower molecular weight (71,000) than normal PS (73.000). binds normally t o C4b-binding protein, and retains full activated protein C cofactor activity. The alteration in the PS Heerlen molecule was identified as a substitution of Serm by Pro, which is due to ROTEIN S (PS) is a vitamin K-dependent plasma P glycoprotein that plays an important role in the regulation of blood coagulation.' It is the nonenzymatic cofactor of the serine protease activated protein C (APC) that inactivates the activated cofactors Va and VIIIa by limited proteolysis in the presence of phospholipids and Ca2+ ions.'z3 PS exerts its cofactor activity by forming a 1: 1 stoichiometric complex with APC.' This complex has a much higher affinity for binding to negatively charged phospholipid membranes than APC alone.4 APC has not only anticoagulant properties but also profibrinolytic properties, some of which are completely dependent on the availability of PS.5,6
gene. The substitution occurs in the consensus sequence for the potential N-linked glycosylation of Am4". Digestion with N-glycanase showed that normal PS probably contains three N-linked oligosaccharide side chains, while PS Heerlen contains only t w o (Asnm not glycosylated?). Segregation analysis in the t w o original families showed that the presence of the genetic abnormality was always associated with the PS-Heerlen phenotype. The frequency of the PS-Heerlen allele was found t o be 0.52% in the general population and 0.67% in a population of patients with unexplained thrombophilia. There is no evidence that the PS Heerlen allele is associated with an increased risk for thrombosis. 0 1990 by The American Society of Hematology.
The importance of the regulatory role of PS in blood coagulation has been established by the identification of families with a hereditary PS In these families the affected heterozygotes are at risk to develop venous thrombo-embolic disease a t a relatively young age.2' The clinical symptoms of hereditary PS deficiency are very similar to those of the clinically dominant form of hereditary protein C deficiency.22 PS deficiency inherits as an autosomal dominant disorder. It has an estimated prevalence of 1: 20,000 in the population a t large, and will account for about 10% of the families with hereditary thr~mbophilia.~~ Recently it has been demonstrated for one family with PS deficiency that the phenotype of thrombophilia and reduced plasma PS levels were linked to a defect in the PS locus (small deletion in the PSa-get~e).'~ In the laboratory, the diagnosis of PS deficiency is made by measuring the concentration of total PS (free and C4bBP-complexed PS) in plasma. Several immunologic assays for PS are a~a i l a b l e . '~,~~.~~ In our laboratory we recently developed two different enzyme-linked immunosorbent assays (ELISA) for total PS.27 One of these (ELISA,) uses polyclonal rabbit anti-PS immunoglobulin G (IgG) both as catching and tagging antibody. The other (ELISA,) uses the same polyclonal anti-PS IgG as catching antibody and a murine monoclonal anti-PS IgG (S-12) as tagging antibody.
In the present study we describe a variant PS molecule (PS Heerlen) that was not recognized by the monoclonal antibody (MoAb) (S12) used in ELISA,. Further analysis showed that the molecular abnormality in PS Heerlen was due to a unique T-C transition in the PSa-gene that resulted in substitution of 460Ser by Pro within a potential glycosylation site. This substitution has no influence on the functional properties of the PS molecule, and therefore has to be considered as a neutral dimorphism. The prevalence of the PS-Heerlen allele was estimated to be 0.52% in healthy blood donors and 0.67% in patients with unexplained thrombophilia.
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MATERIALS AND METHODS
Venous blood was collected in %O v01 0.11 mol/L trisodium-citrate; plasma was prepared by centrifugation of the blood at 3,000 rpm for 10 minutes. Supernatant plasma was rendered platelet-free by subsequent centrifugation at 16,OOOg for 20 minutes at 4OC. Platelet-free plasmas were stored at -20°C or -70°C. Pooled normal plasma was prepared from the platelet-free plasmas of 66 healthy volunteers (46 males, 20 females, mean age 33.9 years) and stored in 0.4-mL aliquots at -70°C.
Protein C antigen, factor I1 antigen, and factor X antigen were measured by electroimmunoassay as previously described.28 Total PS antigen was measured with two different ELISAS.,' In ELISA, immunopurified rabbit anti-PS IgG was used both as catching and tagging antibody, while in ELISA, an MoAb against PS (S-12) was used as the tagging antibody. ELISA plates were coated with immunopurified polyclonal anti-PS IgG, (20 pg/mL) and blocked with 2% bovine serum albumin. After washing with phosphate-buffered saline-Tween (67 mmol/L Na,HP04, 14 mmol/L KH,P04, 0.1% Tween-20, pH 7.9, 100 pL of diluted test sample or standard (pooled normal plasma) was added to the wells and incubated for 18 hours at room temperature. Assay plates then were washed five times before 100 pL/well of enzyme-labeled anti-PS-IgG was added (immunopurified anti-PS-IgG-HRP in ELISA, and S-12-HRP in ELISA,). After a 45-minute incubation at room temperature plates were washed five times. Subsequently 100 pL/well of substrate solution (2.2 mmol/L orthophenylenediamine-dihydrochloride, 0.12 mL/L H,O,, 22.2 mmol/L citric acid, and 51.4 mmol/L NaH,PO,.H,O, pH 5.0) was added. After a 30-minute incubation at room temperature the reaction was stopped with 100 pL/well of 4N H,SO,, and the absorbance at 492 nm was measured using a multichannel analyzer (Titertek Multiskan Plus, Flow Laboratories, Irvine, UK). The assay was calibrated with dilutions of pooled normal plasma (1/500, 1/1,000, 1/2,000, 1/ 4,000, 1/8,000, 1/16,000, 1/32,000, and buffer). Results are expressed in units per milliliter (U/mL), where 1 U represents the amount of coagulation factor present in 1 mL of pooled normal plasma.
The APC cofactor activity of the free PS in plasma samples was measured as previously describedJ5 One hundred microliters of test plasma was incubated with 100 pL of Cephotest (Nycomed & Co, AS, Oslo, Norway) for 6 minutes at 37°C. Subsequently, 5 pL APC (3.1 pmol/L) was added. After a further 30-second incubation at 37"C, 200 pL of 0.017 mol/L CaCl, was added and the clotting time was determined in a Schnitger coagulometer (Amelung, Lieme, West Germany). PS-deficient plasma was prepared by immunodepletion of normal plasma as previously described.,' Free PS was separated from the PS-C4bBP complex by polyethylene glycol (PEG) precipitation as described by Malm et al. 29 The concentration of free PS antigen in the PEG-supernatant was measured by ELISA, (see above).
Removal of N-linked oligosaccharides from PS normal and PS Heerlen was accomplished by the use of N-glycanase (Genzyme, Boston, MA). Twenty microliters of barium citrate eluates containing 0.5% sodium dodecyl sulfate (SDS) was heated for 3 minutes at 100°C before 22 pL 0.55 mol/L sodium phosphate (pH 8.6), 10 pL 7.5% NP-40, and 2.5 pL glycanase (250 U/mL) were added. These mixtures were subsequently incubated at 37°C for various time intervals before analysis by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting with S-19. Complete removal of N-linked oligosaccharides was achieved within 24 hours of incubation.
Antiserum against PS was obtained by immunizing rabbits with the purified human protein.*' Polyclonal antibodies against the Blood collection.
Assays.
non-Ca(I1)-dependent conformation of PS were isolated by immun o a h i t y chromatography on PS-Sepharose as previously des~ribed.~' Murine MoAbs against human PS were prepared according to standard procedures as described elsewhere." The MoAbs S12 and S19 bind equally efficiently to native PS, thrombin-inactivated PS, and Gla-domainless PS. They recognize two different epitopes on the PS molecule as concluded from competition experiments, and they do not affect the APC-cofactor activity of PS or its affinity for the C4b-binding pr~tein.~" Antibody-rich ascites fluid was obtained after intraperitoneal injection of cloned hybridoma cells in Balb-C mice. S12 and S19 Igs were purified from ascites fluid using protein A Sepharose ~hromatography.~' Enzyme-labeled Igs were prepared by coupling the enzyme horseradish peroxidase (HRP) to the anti-PS IgG (polyclonal or monoclonal) using N-succinimidyl 3-(2-piridyl-thio) propionate (SPDP), as previously described."
One-dimensional slab gel elecrophoresis was performed in the presence of SDS as described by Laemli,', using a 3% acrylamide stacking gel and 5% to 15% acrylamide gradient in the separating gel. Transfer to nitrocellulose sheets (Schleicher and Schuell, Dassel, West Germany) was performed according to the method of Towbin et Subsequently, PS-containing protein bands were identified using murine monoclonal anti-PS antibodies (S12, S19) coupled to HRP. Peroxidase activity was visualized with 3,3' diaminobenzidine.
PS was isolated from human plasma essentially as described previou~ly.~~ PS was partially purified from patient plasma using barium citrate adsorption and elution. One milliliter of citrated plasma was mixed with 80 pL of 1 mol/L BaCl, and 20 pL 1 mol/L benzamidin for 30 minutes at room temperature. After centrifugation the pellet was washed with 0.5 mol/L BaCl,, 20 mmol/L benzamidine, and centrifuged. The pellet was then dissolved in 0.5 mL 0.1 mol/L Tris-HCL, 0.1 mol/L EDTA, 20 mmol/L benzamidine (pH 7.9, and dialyzed extensively against 50 mmol/L Tris-HCL, 0.1 mol/L NaCl (pH 7.5).
Isolation and characterization of PS genomic clones. Human genomic libraries were constructed in phage XEMBL3 and 4 (Promega Biotec, Madison, WI).34 DNA, isolated from peripheral blood leukocytes, was partially digested with Sau3A or EcoRI and ligated in the phage arms (XEMBL 3 and 4, respectively). The recombinant DNAs were packaged using an in vitro packaging extract (Promega Biotec) and plated on Escherichia coli NM 539. The two genomic libraries each contained approximately 5 xl0' independent recombinants. Screening of the recombinants was performed by in situ hybridization of the plaque^'^ with PS cDNA fragments,I6 radiolabeled by random priming with a kit from Boehringer Mannheim (Mannheim, West Germany) using (cY-'~P)~CTP (greater than 3,000 Ci/mmol) (New England Nuclear, Boston, MA). Positive clones were plaquepurified and DNA was isolated by the plate lysate method.34 Clones containing the exon coding for the glycosylation consensus sequence were selected by screening with the oligonucleotide PS-GLY (CTG-GTAACACAGTGCCC) coding for residues 487 through 493 (reference 16, see Fig 5 ) that had been endlabeled with T4-polynucleotide kinase (Boehringer Mannheim) using (y-"P)dATP (greater than 5,000 Ci/mmol) (Amersham International, Amersham, UK). EcoRI fragments of the positive clones were subcloned into plasmid pUC13, and the nucleotide sequence was analyzed by the dideoxy-chain termination method of Sanger et al" using (a-"S) dATP (greater than 600 Ci/mmol) (Amersham International) as described by the manufacturers (Boehringer Mannheim). The sequencing reactions were primed with oligonucleotides specific for the PS genomic sequences. Oligonucleotides were synthesized on a Cyclone DNA synthesizer (Millipore, Bedford, MA).
DNA amplification and analysis. The exons coding for residues 457 through 507 of PS were amplified with the polymerase chain reacti~n?~.~' with the primers PS-G53 (GTGCATTGATCATGCT-TCTG) and PS-G35 (CTGTATTMTCAGAGGTGG). The amplification was performed in 32 cycles consisting of a 60-second denaturation at 95OC, a 42-second annealing at 50%. and a 2-minute primer extension at 65%. The reaction mixture contained 500 ng of high molecular weight human DNA from peripheral blood leukocytes or 1 ng of the recombinant DNA of the clones XPSa-2 or APSO-2 as template; 400 ng of each primer; 150 mmol/L of each dNTP 100 pg/mL bovine serum albumin ( S A ) ; 67 mmol/L Tris-HCL (pH 8.8); 6.7 mmol/L MgCI,; 10 mmol/L O-mercapte ethanol 6.7 pmol/L EDTA, 16.6 mmol/L (NH&SO,; 10% DMSO in a final volume of 100 p k and 40 U/mL of Taq-DNA polymerase (Amersham International). The amplified DNA was purified by ultra-low gelling temperature gel electrophoresis. The excised DNA fragment was directly sequenced without further purification. The sequencing reaction was performed by the dideoxy-chain termination reaction as described above. The amplification primers were used as specific primers for the sequencing reaction. The excised fragment was further subjected to restriction analysis for the identification of the PS-Heerlen mutation.
Oligonucleotide hybridization. Two oligonucleotides were synthesized: PS-normal (GATAATGTATCCAGTGCTG), and PSHeerlen (GATAATGTACCCAGTGCTG) specific for the normal and variant PS allele. DNA was isolated from peripheral blood leukocytes and amplified using the primers PS-G53 and PS-G35. The amplified DNA was denatured in 0.2 N NaOH for 5 minutes at room temperature, and 5 pL was spotted on gene screen plus filters (New England Nuclear). The filters were neutralized in 0.5 mol/L Tris-HC1 (pH 7 3 , 1.5 mol/L NaCl, and subsequently air-dried. Prehybridization and hybridization were performed in 6X SSC (0.9 mol/L NaC1, 0.09 mol/L sodium citrate), 5X Denhardt's (0.1% Ficoll, 0.1% polyvinyl pyrrolidone, 0.1% BSA), 0.5% SDS, and 100 pg/mL salmon sperm DNA at 42OC. The filters were probed with PS-normal and PS-Heerlen endlabeled by T4-polynucleotide kinase using (T-~*P) dATP as described. The filters were rinsed twice for 15 minutes in 6X SSC, 0.5% SDS at 58OC. The filters were autoradiographed at -7OOC using an intensifying screen.
RESULTS
PS Heerlen phenotype.
In our laboratory we recently developed two ELISAs for total PS antigenF7 In ELISA, immunopurified non-Ca( 11)-dependent plyclonal antibodies against PS were used both as catching and tagging antibody, while in ELISA, the same plyclonal antibodies were used as catching antibodies, and a murine MoAb against PS (S-12) was used as the tagging antibody. The performance and specificity of both ELISAs were carefully compared with that of the immunoradiometric assay previously developed in our l a b o r a t~r y .~~,~' When it had been established that the three different assays (ELISA,, ELIS&, and IRMA) gave identical results in healthy volunteers, heterozygotes for PS deficiency and patients on oral anticoagulant treatment (ratio PS-ELISAJPS-ELISA,, is 0.97; range 0.85 to 1.12), ELISA, was introduced in the routine laboratory diagnosis of hereditary PS defi~iency.'~ About 6 months later a patient was referred to our center who at the age of 24 years had experienced a deep vein thrombosis in the right leg. At the time of the blood collection the patient was treated with marcoumar. Initial analysis of the patient's plasma with ELISA, indicated that the patient had no detectable PS antigen (Table 1 ). This unexpected result was confirmed in the subsequent analysis of the same and a second blood sample. However, when we analyzed the same samples with ELISA, significant amounts of total PS antigen were found that would be consistent with a type I PS deficiency, according to the criteria previously developed for the laboratory diagnosis of PS deficiency during oral anticoagulant treatment." At that time we suspected that the patient might be both heterozygote for a type I PS deficiency and heterozygote for an abnormal PS molecule (PS Heerlen), which is not recognized by the MoAb (S12) used in ELISA,.
Family studies were performed to investigate this hypothesis further. The results of this analysis (Table 2) confirmed our hypothesis: the mother (11-6) of the proband is a heterozygote for type I PS deficiency, while the father (11-5) is heterozygote for the abnormal PS molecule. Both the proband (111-2) and one of his brothers (111-1) are heterozygotes both for type I PS deficiency and the variant PS molecule. The sister of the proband (111-3) has a type I PS deficiency, while his other brother (111-4) is a heterozygote for the variant molecule: PS-ELISAJPS-ELISA, is 0.67, which is considerably lower than the lower limit of this ratio (0.85) in healthy volunteer^.^^ Figure 1 shows part of the pedigree of the proband. In the family of the father, only his sister 11-4 has a history of venous thrombosis (first episode at the age of 64). She has normal PS antigen (both by ELISA, and ELISA,) and normal PC and At111 antigen. In the family of the mother two additional type I PS deficiencies were identified: patient 11-9 and one of his daughters (not shown). Except for the proband (111-2), none of the type I PS deficiencies from this pedigree (11-6, 11-9, 111-1, 111-2, 111-3) has experienced documented thrombotic episodes.
In the meantime we have identified a second family where two siblings are compound heterozygotes for type I PS deficiency and the variant PS molecule (Table 3 , Fig 2) . Also in this family, the type I PS deficiency was inherited from the mother and the variant PS molecule from the father. Both The laboratory analysis of the aforementioned two families clearly established the autosomal transmittance within these families of a variant PS molecule that is characterized by its lack of reactivity with the MoAb S-12. In a first attempt to define the biochemical alteration in the PS variant. we compared apparent molecular weights of the wild type and variant PS. Therefore, the barium-citrate eluates of plasma of the proband of pedigree S-71 (see Fig 1) and of his father and mother were subjected to SDS-PAGE. transferred to nitrocellulose sheets, and incubated with an MoAb to PS (S-19) conjugated to HRP (Fig 3) . After staining, wild type PS can be identified as the 73-Kd band in pooled normal plasma and purified PS. The variant PS of the proband (111-2) has a significantly lower molecular mass of 71 Kd.
The PS of the mother. who is a heterozygote for type I PSdeficiency, has a normal molecular mass (73 Kd), whereas the PS of the father shows both the 73-Kd and 71-Kd forms of PS. The latter would be in agreement with the previous observation that the father is a heterozygote for the variant PS molecule. These data suggest that the variant PS molecule which is not recognized by the s-12 MoAb has a significantly lower apparent molecular mass. Therefore, we wouldexpect that the 71-Kd PSdoes not react with theS-12 MoAb. The experiment of The IO-kb and S.1-kb EcoRl fragments w m previously reported to belong to each one of the two Ps genes." Therefore. the two clones w m considered to represent the Pscr-and PSB-gene. The oligonucleotide PS-GLY hybridited only with the 1.2-kb fragments of the EmRl digests of both clones. Therefore. these fragments were subcloned into the plasmid pWC13 and sequenced as outlined in Fig 5. The sequences obtained for the two fragments. representing the two PS genes. were almost identical (see Fig 5) . Both genomic fragments contain the exon coding for Asn"' to Figure 6 show part of the nucleotide sequence of the amplified DNA fragments of A&-2. APSd-2. a normal individual. and the Heerlenvariant 111-2 (Fig 1) .
In this part of the sequence. the PSu-gene differs only at one position from the PSB-gene (indicated in Fig 6 by an arrow pointing to the right): the &-gene amtains a C and the P'S&gene contains, as expected. a T in that position. At the corresponding position. the amplified DNA fragmenu of the normal and the Heerlen variant contain both a C and a T. indicating that both genes have been used as template for the amplification. In addition. the PS Heerlen variant has an additional G at a position also showing an A. This G nucleotide was also present in individual 11-3 (Fig 2) (data not shown). but absent in the normal individual and the clones APSu-2 and E d -2 (Fig 6, arrows pointing to the left) .
The A/T -G/C transition in the Heerlen variant was found in the codon for Scr? TCC is changed into CCC. which codes for a Pro. The Scr at position 460 is part of the consensus sequence (Asn'Y-Val"'-Serm) for the putative N-linked glyamylation of residue AsdU. Substitution of &r' @ by a Pro will destroy the consensus sequence and thereby eliminate the putative glycosylation of Asn' ". the residue that has been shown to be glyamylated in bovine Ps. ' * Family unulysis. The families of the two probands PSI4 11-3 and pS7I 111-2 were analyzed for the ax~gregation of the Heerlen phenotype (see Tables I and 2 ) and the T -C transition. The relevant DNA sequence was amplified from the isolated genomic DNA using the primers PS-GS3 and PS-G35. The amplified DNA fragments were subsequently screened for the presence of the normal PS sequence and of the Heerlen variant .sequence using the specific oligonucleotides PS-normal and PS-Heerlen (Fig 7) . All individuals that were heterozygotes for the PS Heerlen variant did react 11-6. 111-1. 111-2. 111-3. ond 1114) (Fig 8) . sequence Asn"n-Val-Ser and therefore will eliminate the putative glycosylation of A d s n . When indeed in PS normal Asn"" contains an oligosaccharide side chain, the substitution could explain the lower molecular weight of PS Heerlen (see Fig 3) .
I V t L l I R ? S T C t C V n L A L V S C N N
A p h -2 M~T A l T C C R C A T C C
I n that caw. one would expect that removal of the N-linked oligosaccharides would abolish the aforementioned Defective glycosylarion of PS Heerlen. Heerlen. Therefore. we incubated crude preparations of PS normal and PS Heerlen with the enzyme N-glycanasc. which detaches asparaginelinked oligosaccharides from glycoproteins to give free oligosaccharide(s) and a protein containing aspartic acid at the glycasylation site. The result of such an experiment is shown in Fig 9. Comparison of the panels A and B shows that the treatment with N-glycanase abolishes the difference in molecular weights for PS normal and PS Heerlen. The observation that the molecular mass of the oligo-saccharide-free PS (61 Kd) is considerably lower than that of undigested PS Heerlen (68 Kd) suggests that PS normal contains more than one N-linked oligosaccharide side chain. In agreement with this hypothesis is the fact that multiple PS bands are found in preparations of PS normal and PS Heerlen that have been partially digested with N-glycanase (panel B in Fig 9) . For PS normal we find PS forms of 72. 68. 64, and 61 (very weak) Kd, while for PS Heerlen we find PS forms of 68. 64. and 61 Kd. These observations strongly suggest that PS normal contains three different N-linked oligosaccharides, while PS Heerlen contains only two N-linked oligosaccharides. are heterozygotes for a hereditary type 1 PS deficiency and that were not treated with oral anticoagulants at the time of the blood collection. These plasmas were considered to contain only 50% normal PS (0.49 to 0.69 U/mL). On the other hand we selected the plasma of patient S71 111-1 (Table 2) . who is a heterozygote both for type I PS deficiency and for the PS-Heerlcn allele. as a plasma containing only PS Heerlen (0.51 U/mL). In all plasmas we measured the APTT in the absence and presence of APC. From Table 4 it is clear that the prolongation ratio, APTT ( + A X ) / APTT( -A X ) , is not different for the plasmas containing normal PS (ratios: 3.79 to 5.15) and the plasma containing PS Heerlen (ratio 4.10). At these levels of PS antigen (0.49 to 0.69 U/mL) the prolongation ratio is significantly higher than that in PSdeficient plasma (less than 0.01 U/mL). but significantly lower than that in pooled normal plasma (1.0 U/mL). Because only the free form of PS has APC cofactor activity, the results of Table 4 also indicate that the PS Heerlen is similarly distributed over free-and C4bBP complexed forms as normal PS. This was confirmed by measuring free PS Heerlen levels after PEG precipitation in plasmaof patients PS71 111-1 and 111-2 (data not shown).
Prevalence of the Heerlett-genotype. The prevalence of the PS-Heerlen genotype in the healthy normal population was estimated by amplification of the DNA sequence coding for Asn"' to Glnw' of PS using the primers PS-G53 and
The amplified fragments were screened with the oligonuclmtides PS-Heerlen and PS-normal, which are spccific for the Heerlen and normal PS allele.
In To investigate the possibility that the PS-Heerlen allele is associated with an increased risk for thrombosis, we also estimated the prevalence of the PS-Heerlen genotype among patients with an unexplained history of venous thromboembolism. In this study, plasma of 1.182 Dutch patients with unexplained thrombophilia were analyzed for total PS anti-gen both with ELISA, and ELISA,. Of the 1,182 patients, 16 showed to be heterozygotes for the PS-Heerlen phenotype, so that we can estimate that in this patient population the prevalence of the PS-Heerlen allele is 16 of 2,364 alleles or 0.68%, which is very similar to what was found in the general population.
DISCUSSION
The PS-Heerlen phenotype is characterized by the lack of reactivity of PS-Heerlen with the MoAb S12 (Tables 1  through 3, Fig 4) . Analysis of the pedigree PS71 and PS14 (Tables 2 and 3 ) demonstrated that the transmission of the phenotype follows autosomal inheritance. Further biochemical analysis of the PS-Heerlen showed that the variant molecule has a slightly lower apparent molecular weight (71,000) on nonreduced gels when compared with the wild type protein S (73,000). This observation suggested to us the possibility that the PS-Heerlen lacked a glycosylation site that was present in normal PS. In human PS there are three potential N-glycosylation sites ( A~n~~~-V a l -S e r , A~n~~' -V a lThr, and Asn4''-Asn-Thr), which are localized on a 30-amino acid peptide in the carboxyterminal loop of the PS molecule. Therefore, we explored the possibility to use the polymerase chain reaction to amplify that part of the PS gene which codes for that particular region of the PS molecule. To attain this goal two problems had to be solved: first of all we needed to identify the exon in the PS gene that codes for Thr4" and to determine the nucleotide sequence a t the intron-exon junctions. Secondly, because the PS locus contains both an active gene (PSa-gene) and a pseudogene (PSP-gene)," we needed the information on the nucleotide sequence of the relevant exon of both PS genes. Therefore, we screened our genomic PS clones with the oligonucleotide PS-Gly, which contains amino acid residues 487 through 493, and succeeded in identifying two clones, XPSa-2 and APSO-2, which contained the PS-Gly sequence and were derived from the PSa-and PSP-gene, respectively. After subcloning of the hybridizing fragments in pUC 13 and determination of its nucleotide sequence (see Fig S) , it was established that the nucleotide sequence coding for to Glnso7 of the mature PS molecule was contained in one single exon, both in the PSa and PSP genes. At the nucleotide level the PSa-and PSP clones differ in this region in four positions (see Fig S) , only three of which will result in amino acid substitutions: Val467 -Ile, Arg474 -His, Thr477 -Met.
Subsequently we used two oligonucleotides (PS-G53 and PS-G35) as primers for the amplification of a 190-bp fragment, which contained the coding sequence for all three putative glycosylation sites. As templates we used the genomic clones XPSa-2 and APSO-2, and genomic DNA of one normal individual and two unrelated patients with the PS-Heerlen phenotype. Direct sequencing of the amplified fragments showed that (1) the fragments of both the PSagene and the PSP-gene had been amplified, and (2) both PS Heerlen fragments showed an additional G at a position also showing an A, and that this G was absent in the fragment of the normal individual. This A/T -G/C transition was found in the codon for Ser460. TCC is changed into CCC, which codes for a Pro. The Ser460 is part of the consensus sequence (Asn-Val-Ser) for the putative N-linked glycosylation of Am4? interestingly, has been shown to be glycosylated in bovine protein S.39 Because the A + G transition introduced a new unique site for the restriction enzyme RsaI, double digestion of the amplified fragment with Sty1 and RsaI could be used to localize the A -G mutation in the active PSa-gene.
In subsequent studies using gene amplification and hybridization with the oligonucleotides PS-normal and PS-Heerlen, it was established that in the PS-71 and PS-14 families there was complete cosegregation between the phenotype of PSHeerlen and the presence of the A -G mutation. Therefore, we conclude that the A -G mutation, which results in the substitution of 460Ser by Pro, is the cause of the phenotypic behavior of the PS-Heerlen molecule (lack of reactivity with the S-12 MoAb). The important question now is whether the substitution of Ser460 by Pro will prevent the N-glycosylation of and whether this substitution interferes with the biologic activity of the molecule.
The experiments summarized in Fig 9 showed that PS normal has probably three N-linked oligosaccharide side chains, while PS Heerlen has only two of these side chains.
The observation that after completed digestion with Nglycanase, PS normal and PS Heerlen have identical molecular weights indicates that the slightly lower molecular weight observed for native PS Heerlen is associated with a lower degree of glycosylation. Together, the results of the experiments of Fig 9 fully support the hypothesis that the substitution of Ser460 by Pro prevents the glycosylation of Moreover, they give preliminary evidence that in PS normal probably all three putative N-glycosylation sites Am4@, Am4") contain oligosaccharaide site chains. The experiments summarized in Table 4 demonstrate that, at about the same level of PS antigen in plasma, PS-Heerlen has virtually identical APC-cofactor activity as normal PS, indicating not only that the biologic properties of the PS molecule are not affected by the substitution but also that the equilibrium binding to the C4b-binding protein is not altered. This finding is in agreement with the observation that the S12-antibody has no effect on the APC-cofactor activity of normal PS, and does not interfere with the binding of PS to the C4b-binding protein. 30 In a recent publication by Schwartz et a1: ' a variant PS molecule with a slightly reduced apparent molecular weight was reported in the plasma and platelets of a patient who also was heterozygous for type I PS deficiency. These investigators demonstrated that treatment of the normal and variant PS with N-glycanase abolished the difference in molecular weight; this observation lead them to conclude that the variant PS molecule lacked a carbohydrate side chain. Because we demonstrated that in The Netherlands the prevalence of the PS-Heerlen allele is rather high (about 0.6%), it is likely that the variant PS reported by Schwartz et alm is identical to PS-Heerlen.
The fact that we could not find any indication for a functional defect in the PS-Heerlen molecule, combined with the observations that the PS-Heerlen allele is as frequent in the general population as in a population of patients with unexplained thrombophilia, strongly suggests that the presence of the PS-Heerlen allele is not associated with a thrombotic risk. This is confirmed by the lack of a family history of thrombosis in the families of patient PS71 11-5 and The use of well-characterized MoAbs in immunologic assays is generally considered as a methodologic improvement. This was one of the reasons that we decided to develop an ELISA for total PS antigen that was based on the use of an MoAb against PS (S-12) as a tagging antibody. Before this ELISA, was introduced in the routine laboratory analysis for PS deficiency, it was carefully established that identical results were obtained with the ELISA as with the IRMA (which is based on the use of polyclonal antibodies against protein S)25 in a panel of plasmas of healthy volunteers (n = 40), PS-deficient patients (n = 40), and patients on oral anticoagulant therapy (n = 40). 27 Nevertheless, it appeared that the S-12 MoAb failed to react with a variant PS molecule (PS-Heerlen), which is present in about 1% of the general population. Fortunately, we recognized the problem after the identification of two PS14 1-1.
unrelated patients who were heterozygotes for both type I PS deficiency and the PS Heerlen allele; otherwise we would have diagnosed all thrombophilic patients who were heterozygotes for the PS-Heerlen allele as type I PS deficiencies. When we realize that in our patient population the prevalence of type I PS deficiency is 2% to 3% and the prevalence of the PS-Heerlen genotype is 1%, we can estimate that the use of the ELISA, for the routine laboratory diagnosis of PS deficiency will result in 25% to 30% false diagnoses of type I PS deficiency. Therefore, our findings may be considered as a serious warning for those of us who intend to introduce MoAbs in immunologic assays that are used for the identification of patients with rare congenital disorders (prevalence PS deficiency in the general population is about 1 of 20,000).~~
